Piper Sandler Downgrades Axonics to Neutral, Lowers Price Target to $71
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Adam Maeder has downgraded Axonics (NASDAQ:AXNX) from Overweight to Neutral and reduced the price target from $75 to $71.

January 12, 2024 | 1:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Axonics was downgraded by Piper Sandler from Overweight to Neutral, and the price target was lowered from $75 to $71.
The downgrade from Overweight to Neutral by a prominent analyst suggests a less optimistic outlook on Axonics' stock performance. The reduction in the price target further implies that the expected future price is now lower than previously estimated, which could lead to a negative short-term impact on the stock price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100